AI in healthcare is accelerating fast—but adoption without governance is risk. In this conversation, oncology and health policy leaders break down how clinicians and health systems should evaluate emerging AI tools: what FDA clearance vs approval really means, why “not FDA-approved” doesn’t automatically mean unsafe, and how laboratory-developed tests (LDTs) are already embedded in everyday care. We also explore real-world evidence, model drift, and why implementation—not innovation—is the true bottleneck for safe scale. If you’re assessing AI in imaging, diagnostics, clinical decision support, or workflow automation, this is your framework for asking smarter questions and protecting patients.

Digital twins are moving from engineering into healthcare and the implications are profound. From oncology decision-making to clinical trials and personalized medicine, virtual human twins could reshape how clinicians predict outcomes, reduce toxicity, and tailor treatment. Dr. Sanjay Juneja and Dr. Doug Flora are joined by digital twin leaders Jim St. Clair and Professor James Fargason to explore how real-time data, AI, and system-level modeling can move medicine beyond population averages toward individualized care. This conversation unpacks what a true digital twin requires, why data quality and interoperability matter, and how digital twins may accelerate drug development, improve trial design, and reduce moral injury for clinicians.

Continuous monitoring is reshaping oncology. CEO of AION Biosystems, Sam Barend, joins Dr. Sanjay Juneja, Dr. Douglas Flora, and Dr. David Penberthy to explore how long‑term physiologic tracking, AI‑driven insights, and clinically validated wearables are improving outcomes for patients at high risk of complications. The conversation highlights FDA pathways, reimbursement realities, and the promise of simpler, signal‑focused monitoring that detects patterns earlier and supports safer treatment continuity.